Systematic screening highlights Albemarle Corp (ALB) at a significant valuation discount from its 52-week high of $221.00, with shares currently trading at $117.64—a 47% decline that reflects fundamental pressures in the lithium chemicals sector. The company's market capitalization stands at $13.9 billion with a price-to-book ratio of 1.75, trading modestly above its book value per share of $80.99.

The screening model identifies several operational headwinds through profitability metrics. Return on equity registers at -2.35%, while net margin posts -4.24%, indicating the company operates at a loss despite generating $5.5 billion in trailing revenue (P/S ratio of 2.52). Revenue growth of 7.87% year-over-year demonstrates continued top-line expansion even as bottom-line profitability remains challenged by lithium pricing volatility and capacity expansion costs.

Fundamental strengths identified include:

• Defensive balance sheet positioning with a debt-to-equity ratio of 0.34 and current ratio of 2.23, providing financial flexibility during the current downcycle
• Gross margin of 18.44% retains a foundation for profitability recovery if commodity pricing stabilizes
• Strategic positioning in battery-grade lithium production aligns with long-term electrification trends

Risk factors flagged by quantitative screens:

• Negative operating margin of -1.78% and EPS of -$2.00 reflect acute near-term profitability challenges
• Elevated beta of 1.35 indicates above-market volatility exposure

Relative to specialty chemical peers SHW, ECL, and PPG, Albemarle's valuation multiple compression and negative profitability metrics position the company as a higher-risk, cyclical exposure within the broader chemicals universe.